ClinicalTrials.gg
Not yet recruitingNCT07736521RCTUpdated Jul 30, 2026

Arthrocentesis Versus Botulinum Toxin Injection in Patients With Temporomandibular Joint Disorders: A Randomized Controlled Trial

An interventional study of Arthrocentesis and Botulinum Toxin-A in Temporomandibular Joint Disorders, Temporomandibular Joint Dysfunction Syndrome and Facial Pain, sponsored by Mudher MB Alsunbuli. Not yet recruiting. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-07-30.

Primary conditionTemporomandibular Joint Dysfunction SyndromeRegistry: Temporomandibular Joint DisordersReclassifiedWhy we changed it
Registry
Temporomandibular Joint Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Temporomandibular Joint Dysfunction Syndrome
Why
  1. The study's listed conditions name Temporomandibular Joint Dysfunction Syndrome, a narrower term within Temporomandibular Joint Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Mudher MB Alsunbuli · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if arthrocentesis works as well as botulinum toxin (Botox) injection to treat pain and jaw dysfunction in adults with temporomandibular joint (TMJ) disorders.

The main questions it aims to answer are:

  • Does arthrocentesis reduce pain more, less, or the same as Botox injection?
  • Does arthrocentesis improve jaw opening and function more, less, or the same as Botox injection?
  • What side effects do participants have with each treatment?

Researchers will compare arthrocentesis to Botox injection to see which treatment works better for reducing pain and improving jaw movement in patients with TMJ disorders.

Participants will:

  • Be randomly assigned to receive either arthrocentesis (a joint-washing procedure) or a Botox injection into the jaw muscles
  • Visit the clinic at 1, 3, and 6 months after treatment for checkups and assessments - Rate their pain and have their jaw movement measured at each visit
  • Complete short questionnaires about their jaw function and quality of life
02

Conditions studied

  • Temporomandibular Joint Disorders
  • Temporomandibular Joint Dysfunction Syndrome
  • Facial Pain

Keywords

  • Temporomandibular Joint Disorders
  • Arthrocentesis
  • Botulinum Toxin
  • TMJ Pain
  • Randomized Controlled Trial
  • Botox
  • Maximum Mouth Opening
  • Visual Analog Scale
03

In context

Temporomandibular Joint Dysfunction Syndrome Reclassified

54 studies on the registry are indexed under Temporomandibular Joint Dysfunction Syndrome; 14 are open to participants now.

This study's planned enrollment of 66 is above the median of 49 across 43 interventional studies indexed under Temporomandibular Joint Dysfunction Syndrome.

Browse Temporomandibular Joint Dysfunction Syndrome studies →

Lead sponsor

This is the only study on the registry with Mudher MB Alsunbuli as lead sponsor.

Compared within Temporomandibular Joint Dysfunction Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Temporomandibular Joint Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinically and radiographically confirmed temporomandibular joint (TMJ) disorder, diagnosed according to Wilkes staging or the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD)
  • Age 18 years or older
  • Symptom duration of at least 3 months
  • Unresponsive to conservative therapy
  • Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  • Previous TMJ surgery
  • Systemic rheumatic/inflammatory joint disease (e.g., rheumatoid arthritis, ankylosing spondylitis)
  • Bony ankylosis of the TMJ
  • Pregnancy
  • Known allergy or to botulinum toxin
  • Concurrent use of muscle relaxants, , or anticoagulant medication that may confound treatment effects
  • Unwillingness or inability to attend scheduled follow-up visits
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Arthrocentesis

    Participants will undergo temporomandibular joint arthrocentesis, a minimally invasive joint lavage procedure.

    Procedure: Arthrocentesis

  • Active comparator
    Botulinum Toxin Injection

    Participants will receive an intramuscular injection of botulinum toxin (Botox) into the masticatory muscles (masseter and temporalis)

    Drug: Botulinum Toxin-A

Interventions

  • ProcedureArthrocentesis

    Temporomandibular joint (TMJ) arthrocentesis will be performed under local anesthesia using a standard two-needle technique. Two needles will be inserted into the superior joint space, and the joint will be irrigated with sterile isotonic solution (e.g., Ringer's lactate or normal saline, approximately 100-300 mL) to lavage inflammatory mediators and break minor intra-articular adhesions. The procedure will be performed as a single session by a trained oral and maxillofacial surgeon. Patients will be advised to follow a soft diet and may receive standard analgesics as needed following the procedure.

    Also known as: lavage

  • DrugBotulinum toxin type AStudies of Botulinum toxin type ABotulinum toxin type A pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Botulinum toxin type A (Botox) will be injected intramuscularly into the masseter and temporalis muscles bilaterally. Injection sites will be determined by palpation of muscle bulk and activity during voluntary contraction (patients will be asked to clench their teeth to identify the muscle borders and the point of maximal bulk/tenderness). The total dose will be 25-50 units per masseter muscle and 10-25 units per temporalis muscle, administered as a single session. The procedure will be performed by a trained physician experienced in botulinum toxin injection technique. Patients will be monitored for the onset of muscle relaxation effects, expected within days to weeks following injection.

06

What researchers measure

Primary outcomes

  1. Change in Pain Intensity Measured by Visual Analog Scale (VAS)

    Pain intensity in the temporomandibular joint region will be measured using a Visual Analog Scale (VAS), a 0-10 point continuous scale where 0 indicates no pain and 10 indicates the worst pain imaginable. Participants will rate their pain at rest and during jaw movement/chewing at each study visit. The change in VAS score from baseline to 6 months will be compared between the arthrocentesis and botulinum toxin injection groups.

    Time frame: Baseline, 1 month, 3 months, and 6 months post-treatment

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Nov 2026, 3 months later.

Of 24 interventional studies with no phase under Temporomandibular Joint Dysfunction Syndrome, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 29. This study's planned 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2026
First posted
Jul 30, 2026
StartEst.
Aug 15, 2026
Primary completionEst.
Nov 15, 2026
CompletionEst.
May 1, 2027
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07736521
Lead sponsor
Mudher MB Alsunbuli
Collaborators
Al-Bayan University
Responsible party
Mudher MB Alsunbuli (Assistant Professor Dr., Al-Bayan University) — Sponsor-investigator
First posted
Jul 30, 2026
Start date
Aug 15, 2026 (estimated)
Primary completion
Nov 15, 2026 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Jul 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion